aTYR PHARMA (ATYR) Non-Current Deffered Revenue (2014 - 2016)

aTYR PHARMA (ATYR) has reported Non-Current Deffered Revenue for 3 consecutive years, with $49000.0 the latest figure, recorded in Q1 2016.

• For the quarter ending Q1 2016, Non-Current Deffered Revenue fell 86.72% year-over-year to $49000.0; the trailing twelve-month figure through Mar 2016 stood at $49000.0 (down 86.72% YoY), and the FY2015 full-year result was $130000.0, down 70.79% from the prior year.
• Non-Current Deffered Revenue slipped to $49000.0 in Q1 2016 per ATYR's latest filing, from $130000.0 in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $445000.0 in Q4 2014 and bottomed at $49000.0 in Q1 2016.
• Historically, Non-Current Deffered Revenue has averaged $249166.7 across 3 years, with a median of $251000.0 in 2015.
• The sharpest annual moves came in 2015 and 2016: Non-Current Deffered Revenue slumped 70.79% in 2015, then sank 86.72% in 2016.
• Over 3 years, Non-Current Deffered Revenue stood at $445000.0 in 2014, then plunged by 70.79% to $130000.0 in 2015, then sank by 62.31% to $49000.0 in 2016.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $49000.0, $130000.0, and $211000.0 for Q1 2016, Q4 2015, and Q3 2015 respectively.